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Abstract
Deficiency of hypoxanthine-guanine phosphoribosyltransferase (HPRT) activity is an inborn error
of purine metabolism associated with uric acid overproduction and a continuum spectrum of
neurological manifestations depending on the degree of the enzymatic deficiency. The prevalence
is estimated at 1/380,000 live births in Canada, and 1/235,000 live births in Spain. Uric acid
overproduction is present inall HPRT-deficient patients and is associated with lithiasis and gout.
Neurological manifestations include severe action dystonia, choreoathetosis, ballismus, cognitive
and attention deficit, and self-injurious behaviour. The most severe forms are known as Lesch-
Nyhan syndrome (patients are normal at birth and diagnosis can be accomplished when
psychomotor delay becomes apparent). Partial HPRT-deficient patients present these symptoms
with a different intensity, and in the least severe forms symptoms may be unapparent. Megaloblastic
anaemia is also associated with the disease. Inheritance of HPRT deficiency is X-linked recessive,
thus males are generally affected and heterozygous female are carriers (usually asymptomatic).
Human HPRT is encoded by a single structural gene on the long arm of the X chromosome at
Xq26. To date, more than 300 disease-associated mutations in the HPRT1 gene have been
identified. The diagnosis is based on clinical and biochemical findings (hyperuricemia and
hyperuricosuria associated with psychomotor delay), and enzymatic (HPRT activity determination
in haemolysate, intact erythrocytes or fibroblasts) and molecular tests. Molecular diagnosis allows
faster and more accurate carrier and prenatal diagnosis. Prenatal diagnosis can be performed with
amniotic cells obtained by amniocentesis at about 15–18 weeks' gestation, or chorionic villus cells
obtained at about 10–12 weeks' gestation. Uric acid overproduction can be managed by allopurinol
treatment. Doses must be carefully adjusted to avoid xanthine lithiasis. The lack of precise
understanding of the neurological dysfunction has precluded development of useful therapies.
Spasticity, when present, and dystonia can be managed with benzodiazepines and gamma-
aminobutyric acid inhibitors such as baclofen. Physical rehabilitation, including management of
dysarthria and dysphagia, special devices to enable hand control, appropriate walking aids, and a
programme of posture management to prevent deformities are recommended. Self-injurious
behaviour must be managed by a combination of physical restraints, behavioural and pharmaceutical
treatments.
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Disease name and synonyms
The deficiency of the enzymatic activity of hypoxanthine-
guanine phosphoribosyltransferase (EC 2.4.2.8; HPRT) is
associated with two OMIM items. Lesch-Nyhan syndrome
(OMIM 300322) corresponds with virtually complete
HPRT deficiency and was described by M. Lesch and W.
Nyhan in 1964 [1]. In 1967 Seegmiller, Rosenbloom and
Kelly reported a complete deficiency of HPRT activity as
the cause of the Lesch-Nyhan syndrome [2]. This same
year, Kelly, Greene, Rosenbloom, Henderson and Seeg-
miller described a partial deficiency of HPRT activity asso-
ciated with gout and no neurological involvement [3,4].
This partial deficiency was termed Kelly-Seegmiller syn-
drome or HPRT-related gout (OMIM 300323). Nowadays
it is considered that between both syndromes, a continu-
ous spectrum of neurological involvement is present in
HPRT-deficient patients. The term Lesch-Nyhan variants
has been introduced to include patients with HPRT-
related gout and some degree of neurological involve-
ment, but without the complete Lesch-Nyhan syndrome.
In 1959, before the Lesch and Nyhan description, Catel
and Schmidt described an 18-month old infant with
hyperuricemia, hyperuricosuria and encephalopathy [5].
They termed this clinical syndrome as "Hyperuricemic
encephalopathy". This patient was later shown to suffer
HPRT deficiency.
Definition and diagnostic criteria
HPRT deficiency is characterized by hyperuricemia with
hyperuricosuria and a continuum spectrum of neurologi-
cal manifestations, which depends on the severity of the
defect. These manifestations include severe action dysto-
nia, choreoathetosis, mild to moderate mental retarda-
tion, and self-mutilation in the complete form or Lesch-
Nyhan syndrome [6], that can go unnoticed in the mildest
forms [4].
The association of a psychomotor delay in the first year of
life with hyperuricemia and/or elevated uric acid to creat-
inine ratio suggest the possibility of HPRT-deficiency. On
the other side of the spectrum, a patient with juvenile gout
and elevated urinary uric acid excretion may also suffer
HPRT deficiency.
Epidemiology
HPRT deficiency is inherited as a recessive X-linked trait
[7]. Thus, males are generally affected and women are gen-
erally asymptomatic carriers. At least five women with
Lesch-Nyhan syndrome due to a variety of molecular
mechanisms have been described in the literature [8-15].
The prevalence of the disease is estimated to be 1/380,000
live births in Canada [16], and 1/235,000 live births in
Spain.
Clinical description
Patients with HPRT deficiency are normal at birth. One of
the first signs of the disease may be the observation of
orange crystals in the diapers, or crystalluria with obstruc-
tion of the urinary tract. Other uncommon forms of pres-
entation include renal failure or acidosis with repeated
vomiting. Psychomotor delay, when present, becomes
evident within 3 to 6 months. A delay in the acquisition
of sitting and head support with hypotonia and athetoid
movements may lead to neurological consultation. Self-
mutilation, in the form of lip biting or finger chewing, can
appear as soon as teeth are present [17,18].
Clinical features of HPRT deficiency include: uric acid
overproduction-related symptoms, neurological manifes-
tations, and haematological disturbances.
Hyperuricemia-related renal and articular symptoms
These symptoms are present in all HPRT-deficient patients
and are not related to the severity of the enzyme defect. All
characteristic findings associated with gout may be
present (acute arthritis, tophi, nephrolithiasis or urolithi-
asis, and renal disease). Hyperuricemia-related presenta-
tions include orange crystals in the diapers, crystalluria in
the first years of life, or juvenile arthritis. If the diagnosis
and treatment is delayed, tophi and renal failure may
appear. However, nowadays allopurinol treatment pre-
vents the development of gouty manifestations.
Neurological symptoms
Neurological symptoms may differentiate HPRT-deficient
variants. The presence and severity of these symptoms are
relevant for prognosis. They may reflect the degree of
enzyme deficiency and can render the patient partially or
completely dependent on others for daily activities and
personal care. We have proposed a classification of HPRT
deficiency in four grades according to the severity of the
neurological symptoms (see below) [18]. Other classifica-
tions in three grades have also been proposed [19]. Neu-
rological symptoms affect the motor sphere, cognitive,
and behavioural aspects.
 Motor disorder: In their original report on two affected
brothers, M. Lesch and W. Nyhan [1] described the motor
abnormalities as spasticity and choreoathetosis. However,
in a recent revision by H. A. Jinnah et al. [17], the motor
syndrome of complete HPRT deficiency is best classified
as a severe action dystonia, superimposed on a baseline
hypotonia. Dystonia is generalized to all parts of the body
and its severity may lead to an inability to stand up and
walk, and patients are confined to a wheelchair. Involun-
tary movements such as choreoathetosis and ballismus
are usually present but are not evident at rest. These symp-
toms are associated with voluntary movements and
increase with excitement and anxiety. Dysarthria and dys-Orphanet Journal of Rare Diseases 2007, 2:48 http://www.OJRD.com/content/2/1/48
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phagia and opisthotonus are frequently reported. Corti-
cospinal tract signs such as spasticity, hyperreflexia and
extensor plantar reflex are generally reported in later years
and they may reflect an acquired defect.
In partial HPRT-deficient patients, a complete motor syn-
drome may be present in the most severe forms. In other
patients the grade of dystonia is less severe and appears in
the form of a dystonic gait, speech difficulties, exercised-
induced dystonia or is unapparent.
 Cognitive impairment: The first Lesch-Nyhan description
included mental retardation as a characteristic of the syn-
drome. However complete HPRT-deficient patients, when
evaluated with specific tests for motor difficulties, show
mild to moderate mental retardation. These patients show
attention deficit disorders but the non-verbal intelligence
is well preserved in the majority [20-22].
Partial HPRT deficient patients can present variable
degrees of mental retardation including apparently nor-
mal intelligence, but they usually show various grades of
attention deficit [20].
 Compulsive self-injurious behaviour is the most striking fea-
ture of Lesch-Nyhan syndrome and is only present in
patients with the complete enzyme defect, although some
Lesch-Nyhan patients never show auto-destructive behav-
iour. The patients begin to bite their lips, tongue or fingers
and, without restrictions, important auto-mutilating
lesions can develop [23,24]. The mutilation is not the
result of a lack of sensation (the patients feel pain and are
relieved when protected from themselves) and recently it
has been ascribed to an obsessive-compulsive behaviour.
In some instances, the aggressive behaviour is also
directed against family and friends, with patients spitting
or using abusive language. Self-mutilation may start
between 2 and 16 years of age and, in some instances, is
associated with or aggravated by psychological stress
(adolescence, familial conflicts). Despite their periodic
aggressive behaviour, Lesch-Nyhan patients are frequently
happy and engaging children when they are restrained.
The neuro-behavioural disorder may be markedly modu-
lated by numerous environmental factors, among which
education is the most relevant [25]. Partial patients do not
show self-injurious behaviour but in some cases an obses-
sive-compulsive disorder has been reported.
Haematological aspects
In Lesch-Nyhan patients the presence of megaloblastic
anaemia is frequent and in some cases severe [26]. Micro-
citic anaemia can also be present, usually associated with
hiatus hernia.
Classifications
HPRT deficiency can be classified according to the severity
of the neurological manifestations and the enzyme defect.
The first classification includes HPRT-deficient patients as
complete or Lesch-Nyhan syndrome, and as partial or
Kelly-Seegmiller syndrome [3]. Other classifications
include three groups: classical Lesch-Nyhan or complete
deficiency (LN); HPRT deficiency with neurological man-
ifestations or HPRT related hyperuricemia with neurolog-
ical disability (HRND), and HPRT-related hyperuricemia
(HRH) for partial patients with no evident neurological
manifestations [17]. We have proposed a classification
(Table 1) with four groups based on the clinical, biochem-
ical, enzymatic and molecular data, derived from careful
clinical observation of 22 patients from 18 different Span-
ish families [18]. We have divided the HRND group into
two (Group 2 and 3) because neurological disability in
these patients may vary between severe neurological
symptoms and mild neurological symptoms with various
prognoses.
- Group 1: normal development without neurological symp-
toms. HPRT deficiency in these patients could be mani-
fested as asymptomatic hyperuricemia with elevated uric
acid excretion rates, or as renal lithiasis and/or gout. These
patients are totally independent in terms of daily activities
and lead normal lives. Only when carefully examined,
they may present some minor dystonia, such as exercise-
induce dystonia, attention deficit or obsessive-compulsive
behaviour.
Table 1: Classification of HPRT deficiency based on clinical, biochemical, enzymatic and molecular data.
Partial deficiency (Kelly-Seegmiller syndrome) Lesch-Nyhan
Grade 1 Grade 2 Grade 3 Grade 4
Patients 6 3 2 25
HPRT haemolysate (+) (-) (-) (-)
HPRT erythrocyte (+) (+) (-) (-)
Size of protein altered (-) (-) (-) (+,-)
Self-mutilation (-) (-) (-) (+)
We have proposed a classification in four groups based on the clinical, biochemical, enzymatic and molecular data, derived from careful clinical 
observation of 36 patients from different Spanish families [18]. (+) Present or detectable. (-) Absent or undetectable. (+ -) May be present or not.Orphanet Journal of Rare Diseases 2007, 2:48 http://www.OJRD.com/content/2/1/48
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- Group 2: mild neurological symptoms. These patients have
mild neurological symptoms such as dystonic gait, dysar-
thria, stuttering, and some degree of mental retardation.
They are hampered by their neurological symptoms,
although they are independent in most activities, and can
walk and live on their own.
- Group 3: severe neurological symptoms. Patients are men-
tally normal, can feed themselves and take care of some of
their personal needs, but their severe dystonia confines
them to a wheelchair. These patients do not present self-
injurious behaviour.
-  Group 4: classic Lesch-Nyhan syndrome. These patients
exhibit typical characteristics of Lesch-Nyhan syndrome,
including self-injurious behaviour, choreoathetosis and
ballismus, inability to stand or walk, some degree of spas-
ticity, and are fully dependent on others for daily activities
and personal needs. Some of these patients may not show
auto-destructive behaviour or mental retardation.
This classification has been useful for the 36 HPRT defi-
cient patients that we have diagnosed for the last 23 years
(1984–2007). However, use of this classification system
may require some time for the disease to be fully recog-
nized (i.e. grade 2 and 3 can only be differentiated after 1
year of age).
Aetiology
Uric acid overproduction
Several mechanisms can be identified that contribute to
uric acid overproduction in HPRT deficiency [27,28]. a)
HPRT catalyses the salvage synthesis of inosine mono-
phosphate (IMP) and guanosine monophosphate (GMP)
from the purine bases hypoxanthine and guanine respec-
tively, utilizing 5'-phosphoribosyl-1-pyrophosphate
(PRPP) as a co-substrate (Figure 1). The HPRT defect
results in the accumulation of its substrates, hypoxanthine
and guanine, which are converted into uric acid by means
of xanthine oxidase. b) The increased availability of PRPP
for PRPP amidotransferase, the rate-limiting enzyme of de
novo synthesis of purine nucleotides (Figure 1), increases
purine synthesis. c) On the other hand, there is decreased
formation of PRPP amidotransferase feedback inhibitors,
IMP and GMP. This dual mechanism results in an
increased  de novo synthesis of purine nucleotides. The
combination of deficient recycling of purine bases with
increased synthesis of purine nucleotides explains marked
uric acid overproduction in HPRT deficiency. Elevated
APRT activity may also contribute to purine overproduc-
tion.
Pathophysiology of neurological symptoms
The pathophysiology of the neurological and behavioural
dysfunctions remains unclear [29,30]. Post mortem studies
of brains from Lesch-Nyhan patients have not disclosed
any characteristic morphological abnormality [31,6]. Pio-
neer neurochemistry analysis of post mortem tissues
revealed the first biochemical evidence of dysfunction of
brain neurotransmitters in Lesch-Nyhan syndrome. In
this study, biochemical aspects of the function of
dopamine-neuron terminals in the striatum were
decreased, whereas serotonin and 5-hydroxyindolacetic
were increased [32]. Other biochemical studies of the
Lesch Nyhan patient's cerebrospinal fluid showed a
decreased level of the dopamine metabolite homivanillic
acid, together with increased hypoxanthine and xanthine
concentrations [31,33,34]. More recently, in vivo human
studies with positron-emission tomography, in which lig-
ands that bind to dopamine-related proteins in the brain
have been used, have confirmed alterations of dopamin-
ergic system in Lesch-Nyhan patients [35,36].
Two animal models, pharmacological and knockout, have
been employed in the study of Lesch-Nyhan pathogenesis.
The pharmacological rat model, developed by Breese et
al., supports the relationship between self-injurious
behaviour and dopamine deficit. Newborn animals
treated with 6-hydroxydopamine, which destroys cate-
cholamine-containing neurons, showed self-injurious
behaviour in response to dopa agonist administration
[37]. Unfortunately, HPRT-deficient knockout mice did
not show neurological alterations, but they also presented
an age-related decreased content of dopamine in their
brains [38-40]. Various HPRT-deficient cell cultures have
been developed to study the effects of the enzyme deficit
and purine alterations [41,42] and dopamine deficit has
been confirmed [43,44]. However, we must be careful
when interpreting cell culture results since different
HPRT-deficient cultures have showed different results
[45]. Alterations in other neurotransmitters systems, such
as serotonin [30] or adenosine neurotransmitters systems
have also been implicated in patients with Lesch-Nyhan
symptoms [46-49].
Among the biochemical alterations described in the cen-
tral nervous system of Lesch-Nyhan patients, hypoxan-
thine excess is the most prominent. Toxic effects of this
metabolite have been implicated in the pathogenesis of
neurological dysfunction by means of alteration of adeno-
sine transport [47,49], Na+K+ ATPase activity [50], etc.
Deficit of other purine compounds due to the enzyme
defect is controversial, and altered nucleotide concentra-
tions have been postulated as a possible cause of changes
in G-protein-mediated signal transduction [51].
In summary, various studies have led to the suggestion
that the neurological symptoms of Lesch-Nyhan syn-
drome could be related to a dysfunction of the dopamin-
ergic neurotransmitter system in the basal ganglia, but theOrphanet Journal of Rare Diseases 2007, 2:48 http://www.OJRD.com/content/2/1/48
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relationship between the dopamine deficit and the purine
metabolic disorder is still unknown.
Haematological aspects
Megaloblastic anaemia in Lesch-Nyhan patients is associ-
ated with megaloblastic findings in bone marrow and has
been considered the result of increased folic acid con-
sumption, due to enhanced de novo purine synthesis [52].
Nevertheless, this anaemia is not corrected by folate ther-
apy.
Diagnostic methods
The diagnosis of HPRT deficiency must be supported by
clinical, biochemical, enzymatic and molecular data.
Clinical and biochemical diagnosis
HPRT deficiency should be suspected in patients with
hyperuricemia and uric acid overproduction with or with-
out neurological impairment. During the first year of life,
serum and urine uric acid determinations should be
included in the differential diagnosis of psychomotor
delay. Unfortunately, in previous years Lesch-Nyhan syn-
drome diagnosis has been delayed until self-mutilation
was evident. Nephrolithiasis and obstructive nephropathy
are common early manifestations in patients with partial
HPRT deficiency.
Neuro imaging tests such as computing tomography (CT)
and magnetic resonance imaging (MRI) may show
Purine metabolism Figure 1
Purine metabolism. The metabolic scheme shows the first and rate-limiting step of de novo purine synthesis mediated by the 
enzyme 5'-phosphoribosyl-1-pyrophosphate (PRPP) amidotransferase, and the salvage pathway mediated by hypoxanthine 
phosphorybosyltransferase (HPRT) and adenine phosphorybosyltransferase (APRT). The de novo synthesis occurs through a 
multi-step process and requires the contribution of four aminoacids, one PRPP, two folates and three ATP to synthesize an 
inosine monophosphate (IMP) molecule. HPRT catalyzes the salvage synthesis of inosine monophosphate (IMP) and guanosine 
monophosphate (GMP) from the purine bases hypoxanthine and guanine respectively, utilizing PRPP as a co-substrate. The 
HPRT defect results in the accumulation of its substrates, hypoxanthine and guanine, which are converted into uric acid by 
means of xanthine oxidase. Elevated APRT activity may also contribute to purine overproduction.
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atrophic non-specific changes [6,53]. Electroencephalo-
grams are not diagnostic.
A high serum urate concentration is usually the biochem-
ical finding that prompts special testing for the specific
diagnosis, although some patients, particularly young
infants, may have borderline serum uric acid levels due to
increased renal clearance of uric acid [54]. Normal values
for serum urate levels depend on age and sex. Similarly,
the urinary uric acid/creatinine ratio can be employed as
a screening test for inherited disorders of purine metabo-
lism [54] but the values should be evaluated based on the
age of the patient. Normal values for the urinary uric acid/
creatinine ratio are below 1.0 after age 3-years. Mean
plasma concentrations of urate, hypoxanthine, and xan-
thine, and their urinary excretion rates, are markedly ele-
vated in HPRT-deficient patients. However, there is a non-
statistically significant difference in these biochemical var-
iables between partial and Lesch-Nyhan patients, except
for xanthine urinary excretion that appears to be increased
in Lesch-Nyhan patients as compared to partial HPRT
deficient patients [55].
Enzymatic diagnosis
HPRT deficiency must be confirmed by enzymatic deter-
minations [56]. Patients present low or undetectable
HPRT activity in haemolysates, with increased adenine
phosphoribosyltransferase (APRT) activity. Lesch-Nyhan
patients (grade 4) present undetectable HPRT activity, but
in partial HPRT-deficient patients HPRT activity in
haemolysate ranges from 0 to 10% [18,19]. Grade 1
patients usually show detectable haemolysate HPRT activ-
ity, while grade 2 or 3 patients generally do not. To better
characterize the HPRT deficiency, enzyme activity can be
measured in intact cells (erythrocytes or fibroblasts). A
correlation was found between residual HPRT activity in
intact erythrocytes and fibroblasts [19,57] and neurologi-
cal involvement, although values may overlap for patients
with very different phenotypes.
Molecular diagnosis
Human HPRT is encoded by a single structural gene span-
ning approximately 45 Kb on the long arm of the X chro-
mosome at Xq26, and consists of nine exons with a
coding sequence of 654 bp [58,59]. Most HPRT-deficient
patients present HPRT mRNA expression [60], and molec-
ular diagnosis can be accomplished by cDNA sequencing
[61]. In other cases, genomic DNA sequencing may be
necessary [62]. Documented mutations in HPRT defi-
ciency show a high degree of heterogeneity in type and
location within the gene: deletions, insertions, duplica-
tions, and point mutations have been described as the
cause of HPRT deficiency. To date, more than 300 disease-
associated mutations have been found [63-65]. Single
point mutations are the main cause of partial deficiency of
the enzyme, whereas Lesch-Nyhan syndrome is caused
mainly by mutations that modify the size of the predicted
protein [64]. HPRT deficiency is inherited as an X-linked
recessive trait. However, about 30% of patients' mothers
are not somatic carriers, and these patients probably carry
de novo mutations due to a germinal cell mutation. Molec-
ular diagnosis in HPRT-deficient patients allows faster
and more accurate carrier and prenatal diagnosis.
Differential diagnosis
Complete HPRT deficiency-associated psychomotor delay
must be differentiated from cerebral palsy. Self-injurious
behaviour is also present in other conditions such as idio-
pathic mental retardation, autism, Tourette syndrome,
Cornelia de Lange syndrome, severe psychiatric altera-
tions, etc. In partial HPRT deficiency, differential diagno-
sis should explore other possible causes of hyperuricemia
and gout. Elevated excretion of uric acid as an indication
of purine overproduction is an important hallmark in the
differential diagnosis. Other causes of hyperuricemia with
purine overproduction include PRPP synthetase superac-
tivity and glucose 6-phosphate deshydrogenase defi-
ciency.
Genetic counselling
Inheritance of HPRT deficiency is X-linked recessive. Thus
males are generally affected and heterozygous female are
carriers. However, at least five females with Lesch-Nyhan
syndrome have been described, with different molecular
alterations accounting for their HPRT deficiency [8,66-
69].
Carrier diagnosis is an important issue for most HPRT-
deficient families. Female carriers cannot be detected
without the help of a laboratory since they are usually
asymptomatic [70]. When the mutation is unknown, car-
rier status can be assessed by biochemical and enzymatic
methods. Most female carriers for HPRT deficiency can be
differentiated from non-carriers when 24-h urine samples
are analysed after a 5-day purine-restricted diet: carriers
have significantly higher urinary excretion rates of hypox-
anthine and xanthine [71]. HPRT activity is most often
normal in haemolysate of the peripheral blood of female
carriers due to selection against HPRT-deficient erythro-
cyte precursors [72]. Enzymatic diagnosis of the carrier
state can be performed by the identification of HPRT-defi-
cient hair follicles or cultured fibroblasts [73] because of
their mosaicism in terms of HPRT activity, although such
diagnosis is not infallible. HPRT-deficient cells from car-
rier females can be selected based on their 6-thioguanine
resistances. Proliferation assay of peripheral blood T-lym-
phocytes in the presence of 6-thioguanine is diagnostic in
most cases [74].Orphanet Journal of Rare Diseases 2007, 2:48 http://www.OJRD.com/content/2/1/48
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When the HPRT mutation has been characterized in the
family, faster and more accurate carrier diagnosis can be
performed by molecular methods [75].
Antenatal diagnosis
Prenatal diagnosis for Lesch-Nyhan syndrome can be per-
formed with amniotic cells obtained by amniocentesis at
about 15–18 weeks' gestation, or chorionic villus cells
obtained at about 10–12 weeks' gestation. Both HPRT
enzymatic assay and molecular analysis for the known
disease-causing mutation can be performed [76,77].
Treatment
Uric acid overproduction
Uric acid overproduction can be controlled with the xan-
thine oxidase inhibitor allopurinol that blocks the conver-
sion of xanthine and hypoxanthine into uric acid [78].
Allopurinol treatment reduces serum urate and urine uric
acid levels and thus prevents uric acid crystalluria, neph-
rolithiasis, gouty arthritis and tophi [4,55,79,80]. Allopu-
rinol should be started as soon as the enzyme deficiency
has been diagnosed, although it has no effect on behav-
ioural and neurological symptoms. In adults, combined
treatment with colchicine prophylaxis may be required to
prevent acute inflammation. In our experience [55], treat-
ment with allopurinol normalized serum urate level in all
patients and resulted in a mean reduction of serum urate
of about 50% and a 74% reduction in urinary uric acid/
creatinine ratio. In contrast, allopurinol treatment
increased mean hypoxanthine and xanthine urinary excre-
tion rates about 5- and 10-fold, respectively, compared to
baseline levels. Allopurinol-related biochemical changes
are similar in patients with either complete or partial
HPRT deficiency. Renal function usually remained stable
or improved with treatment. Allopurinol doses ranged
from 50 to 600 mg/day. The initial dosage of allopurinol
is 5–10 mg/Kg/day and it should be adjusted to maintain
high-normal serum uric acid levels and a urinary uric acid/
creatinine ratio lower than 1.0. Allopurinol is efficacious
and generally safe for the treatment of uric acid overpro-
duction in patients with HPRT deficiency [55]. However,
xanthine lithiasis may develop as a consequence of allop-
urinol therapy [81]. The optimal allopurinol dose for
HPRT-deficient patients has not been established. In our
experience, when serum urate is maintained close to its
solubility threshold, urate deposition does not occur.
Xanthine lithiasis may be prevented by sequential deter-
mination of urinary oxypurines, which should be at a cer-
tain balance with uric acid excretion.
Motor syndrome
The lack of precise understanding of the cause of the neu-
rological dysfunction has precluded the development of
useful therapies. Spasticity and dystonia can be managed
with benzodiazepines and gamma-aminobutyric acid
inhibitors such as baclofen [6]. No medication has been
found to effectively control the extrapyramidal manifesta-
tions of the disease. Physical rehabilitation, including
management of dysarthria and dysphagia, special devices
to enable hand control of objects, appropriated walking
aids, and a programme of posture management to prevent
deformities is recommended.
Behavioural manifestations
Self-injurious behaviour must be managed with a combi-
nation of physical restraints, behavioural and pharmaceu-
tical treatments [82]. Benzodiazepines and
carbamazapine are sometimes useful for ameliorating
behavioural manifestations and anxiety. Stress increases
self-injurious behaviour. Thus, stressful situations should
be avoided and aversive techniques should not be
employed. Instead, behavioural extinction methods have
proven to be partially efficacious in a controlled setting.
However, the cornerstone of day-to-day management of
Lesch-Nyhan syndrome is still adapted physical restraint
to protect patients from themselves. For instance, elbow
restraints allow hand use without the possibility of finger
mutilation, and dental guards prevent cheek biting (Fig-
ure 2). Patients themselves request restrictions and
became anxious if they are unrestrained, and sometimes
Management of self-injurious behaviour Figure 2
Management of self-injurious behaviour. The corner-
stone of day-to-day management of Lesch-Nyhan syndrome 
is still adapted physical restraint to protect patients from 
themselves. For instance, elbow restraints allow hand use 
without the possibility of finger mutilation, and dental guards 
prevent cheek biting. Patients themselves request restric-
tions and became anxious if they are unrestrained.Orphanet Journal of Rare Diseases 2007, 2:48 http://www.OJRD.com/content/2/1/48
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restraints that would appear to be ineffective, such as a
pair of gloves to prevent finger biting, are useful.
Therapies under investigation
Some reports have suggested that gabapentin may
improve self-injurious behaviour and no side effects have
been associated with its use [83]. Other treatments under
investigation for the management of self-injurious behav-
iour are local injections of botulin toxin [84], deep brain
stimulation in globus pallidus [85,86] or dopamine
replacement therapy, but they need to prove to be effica-
cious and safe in the long-term management of these
patients.
Prognosis
With appropriate allopurinol treatment, renal function is
generally preserved [55] and patients survive until second
or third decade of life. Patients with the complete Lesch
Nyhan syndrome are unable to walk and are confined to
a wheelchair. Generally with restriction and medical treat-
ment self-injurious behaviour can be managed appropri-
ately. Causes of death include pneumonia and other
infectious diseases. In some cases sudden and unexpected
death has been reported. This appears to have a respira-
tory rather than a cardiogenic origin [87].
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